Journal Publications

• A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
  

  Accepted for publication, New England Journal of Medicine, 2012

• Outpatient Consolidation Treatment with Clofarabine in a Phase 2 Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML)
  

  Leukemia and Lymphoma.  (Leuk & Lymp: published online Oct. 24, 2011)

• A Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia
  

  Investigational New Drugs.  (Invest New Drugs 2011:published online Sept. 16, 2011)

• Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults with Acute Myeloid Leukemia and Unfavorable Prognostic Factors
  

  Journal of Clinical Oncology. (JCO 2010:28:4:549-555)

• Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma
  

  Blood. (Blood 2010:115:3:475)

• Safety and Efficacy of Romiplostim in Patient with Lower-risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia
  

  Journal of Clinical Oncology. (JCO 2010:28:3:437-444)

• Improved Quality of Life for Romiplostim-Treated Patients with Chronic Immune Thormbocytopenic Purpura: Results from Two Randomized, Placebo-Controlled Trials
  

  British Journal of Haematology, 2009 (Br J Haematol 2009:144(3):409-415)

• Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes
  

  Journal of Clinical Oncology, 2009 (JCO 2009:27:11:1850-1856)

• Recent Advances in Low- and Intermediate-1--Risk Myelodysplastic Syndrome: Developing a Consensus for Optimal Therapy
  

  Clinical Advances in Hematology & Oncology, 2008 (Clin Adv Hem Onc 2008:6(12):1-16)

• Phase 2, Single-arm, Trial to Evaluate the Effectiveness of Darbopoetin alfa for Correcting Anaemia in Patients with Myelodysplastic Syndromes
  

  British Journal of Haematology, 2008 (Br J Haematol 2008:142(3):379-393)

• Safety and Efficacy of Long-Term Treatment with Romiplostim in Thrombocytopenic Patients with Chronic ITP
  

  Blood, 2009 (Blood 2009:113:2151-2171)

• Efficacy of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura: a Double-blind Randomised Controlled Trial
  

  Lancet, Feb. 2, 2008 (Lancet 2008:371:395-403)

• The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndromes
  

  Cancer, March 15, 2007 (Cancer 2007:109(9):1705-1714)

• AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
  

  New England Journal of Medicine, October 19, 2006 (N Engl J Med 2006:355:1672-1681)

• Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period
  

  Clinical and Applied Thrombosis/Hemostasis, October 1, 2006. (Clin Appl Thromb Hemost. 2006 :12(4):389-396)

• Low-Dose Vitamin K to Augment Anticoagulation Control
  

  Pharmacotherapy, October 2005.(Pharmacotherapy 2005:25(12):1746-1751)

• Initial Management of Immune Thrombocytopenic Purpura in Adults: A Randomized Controlled Trial Comparing Intermittent anti-D with Routine Care
  

  American Journal of Hematology, November 2003 (Am J Hematol 2003:74(3):161-169)

Abstracts

• Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-1)
  

  Accepted for publication, 53rd American Society of Hematology Annual Meeting and Exposition, Dec. 10-13, 2011.

• Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-1
  

  Accepted for oral presentation, 53rd American Society of Hematology Annual Meeting and Expostion, Dec. 10-13, 2011.

• Phase I Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra, TLK199) in Combination with Lenalidomide (Revlimid) in Patients with Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
  

  Accepted for poster presentation, 53rd American Society of Hematology Annual Meeting and Exposition, Dec. 10-13, 2011.

• Update of an Open-Label Extension Study Evaluating the Long-Term Safety & Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS)
  

  Accepted for poster presentation, 53rd American Society of Hematology Annual Meeting and Exposition, Dec. 10-13, 2011

• Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP)
  

  Accepted for poster presentation, 53rd American Society of Hematology Annual Meeting and Exposition, Dec. 10-13, 2011.

• 24-Month Analysis of the Impact of Chelation on Clinical Outcomes in 600 Patient Registry of Lower-Risk MDS Patients
  

  Accepted for poster presentation, 53rd American Society of Hematology Annual Meeting and Exposition, Dec. 10-13, 2011.

• Results of Comfort-1, A Randomized, Double-Blind Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib (INCB018424) Versus Placebo for Patients with Myelofibrosis
  

  Presented at the16th Congress of the European Hematology Association, June 9-12, 2011, London, UK

• Update of an Open-Label Extension Study Evaluating the Long-Term Safety & Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes
  

  Leukemia Research (Leuk Res 2011:35:1:S84:#215) Presented by Roger M. Lyons, MD, FACP at the 11th International Symposium on Myelodysplastic Syndromes, Edinburgh, Scotland, May 18-21, 2011

• A 12-Month Follow-Up of an Ongoing Prospective, Non-Interventional, Multicenter Registry in Iron Overloaded Patients with Lower-Risk Myelodysplastic Syndromes
  

  Leukemia Research (Leuk Res 2011:35:1:S85: #217)  Presented by Roger M. Lyons, MD, FACP at the 11th International Symposium on Myelodysplastic Syndromes, Edinburgh, Scotland, May 18-21, 2011

• Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study
  

  Blood 2010:116:#68

• Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes
  

  Blood 2010:116:#1885

• Clinical Parameters in 391 Iron-Overloaded Patients with Lower-Risk MDS Enrolled in a Prospective, Non-Interventional Multicenter Registry
  

  Blood 2009:114:#4834

• Outpatient Treatment with Clofarabine in Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia
  

  Blood 2009:114:#4162

• Clorfarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities
  

  Blood 2009:114:#4155

• Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who > or = 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors
  

  Blood 2009:114:#2083

• Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide
  

  Blood 2009:114:#1770

• Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adults with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors
  

  Blood 2009:114:#2061

• An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS)
  

  Blood 2009:114:#2765

• Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP)
  

  Blood 2009:114:#1770

• Updated Remission Duration and Survival Results of Single-agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia Unlikely to Benefit From Standard Induction Chemotherapy Due to Unfavorable Baseline Risk Factor(s)
  

  J Clin Oncol 2009:27:15s:#7062

• Results of a Phase II Study of Bortezomib in Patients with Relapsed or refractory Indolent Lymphoma
  

  Blood 2008:112:#1572

• Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab Vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia
  

    Blood 2008:112:#327

• Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy
  

  Blood 2008:112:#558

• Self-Injection of Romiplostim by Patients with Chronic Immune Thrombocytopenic Purpura (ITP)
  

  Blood 2008:112:#4707

• Safety and Efficacy of Long-Term Treatment with Romiplostim in Thrombocytopenic Patients with ITP
  

  Blood, Nov. 3, 2008. Accepted for publication

• Rapid Onset of Effectiveness with Three Alternative Azacitidine (AZA) Dosing Regimens in Patients with Myelodysplastic Syndromes (MDS)
  

  Haematologica 2008:93(sl):93:#0232

• Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy
  

  J Clin Oncol 2008:26:#7025(May 20 suppl)

• Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza) in Patients with Myelodysplastic Syndromes (MDS)
  

  Blood 2007:110:11:#819

• Evaluation of AMG 531 Safety in Splenectomized (S) and Nonsplenectomized (NS) Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in Two Randomized Placebo-Controlled Phase 3 Studies
  

  Blood 2007:110:11:#1300

• Health-Related Quality of Life (HRQoL) in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Results from Two Placebo-Controlled Phase 3 Studies of AMG 531
  

  Blood 2007:110:11:#1314

• Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients with Low Risk Myelodysplastic Syndrome (MDS): Update on Extended Treatment
  

  Blood 2007:110:11:#250

• Thrombocytopenia in MDS: Incidence and Impact
  

  Supportive Care Cancer 2007:15:651-797:#P-148

• Tolerability and Hematologic Improvement Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes
  

  J Clin Oncol 2007: 25:18S:#7083(June 20 Supplement)

• Evaluating Safety and Efficacy of AMG 531 for the Treatment of Thrombocytopenic Patients with Myelodysplastic Syndrome (MDS): Preliminary Results of a Phase 1/2 Study
  

  Supportive Care Cancer 2007:15:651-797;#P-150

• The Efficacy and Safety of Darbopoetin Alfa For Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results After 53-55 Weeks
  

  J Supp Oncology 2007:5:4:#14(Suppl.2 April 2007)

• The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndrome
  

  J Supp Oncology 2007:5:4: #74(Suppl.2 April 2007)

• Long-term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-week Update
  

  J Supp Oncology 2007:5:4:#78(Suppl.2 April 2007)

• Baseline Predictors of Response to Treatment with Darbepoeitin-alpha (DA) in Anemic Patients with Low-risk Myelodysplastic Syndrome (MDS)
  

  J Clinical Oncol 2007: 25:18S:#7081(June 20 Supplement)

• Evaluating Safety and Efficacy of AMG 531 for the Treatment of Thrombocytopenic Patients with Myelodysplastic Syndrome (MDS): Preliminary Results of a Phase 1/2 Study
  

  J Clin Oncol 2007:25:18S:#7032(June 20 Supplement)

• The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndromes
  

  Cancer 2007:109(9):1705-14

• Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-blind, Placebo-controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy
  
• The Clinical and Direct Medical Cost Burden of Splenectomy Among Managed Care Patients with Chronic Immune Thrombocytopenic Purpura (ITP)
  

  Blood 2006:108:11:#5536

• Retrospective Matched Cohort Study of Immune Thrombocytopenic Purpura (ITP): Complications Related to Corticosteroid (CS) Use
  

  Blood 2006:108:11:#3295

• Long-term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenia Purpura: 48-week Update
  

  Blood 2006:108:11:#476

• Darbopoetin Alfa for Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Interim Results After 27/28 Weeks
  

  J Clin Oncol 2006: 24:18S:#6564(June 20 Supplement)

• The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndromes (MDS)
  

  Blood 2006:108:11:#2617

• Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes
  

  Blood 2006:108:11:#2662

• The Efficacy and Safety of Darbopoetin Alfa For Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results After 53-55 Weeks
  

  Blood 2006:108:#2671

• Darbepoetin Alfa for Treating Anemia in Patients with Low-Risk Myelodysplastic Syndromes: Exploratory Analysis of Baseline Predictors of Response
  

  J Clin Oncol 2006: 24:18S:#6579(June 20 Supplement)

• Transfusion Independence Assessed During Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes
  

  J Clin Oncol 2006: 24:18S:#6574(June 20 Supplement)

• A Phase 2, Single-Arm, Open-Label Trial to Evaluate the Effectiveness of Darbopoeitin Alfa for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes
  

  Blood 2005:106:11:#2541

• Long-term Dosing of AMG 531 is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura
  

  Blood 2005:106:11:#220

• Azicitidine (Vidaza) Treatment Response Assessed Using Three Alternative Dosing Schedules in Patients with Myelodysplastic Syndromes (MDS)
  

  Blood 2005:106:11:#2517

Publications & Abstracts

• Publications and Abstracts for Roger M. Lyons, MD, FACP
  

Practice Magazine

• Cancer Care Today--A publication from Cancer Care Centers of South Texas
  

  Summer 2011issue

Feature Articles

• Sharon T. Wilks, MD Featured in San Antonio Magazine, May/June 2011
  
• Sharon Wilks, MD Featured in March 2009 Issue of MD News Magazine
  

  MD News. 2009:2:3:4-6.

• Roger M. Lyons, MD Featured in June 2008 Issue of MD News Magazine
  

  MD News. 2008:1:3:4-9.

Clinical Trials Update Research Newsletter

• Clinical Trials Update Research Newsletter--November 2011 Issue
  
• Clinical Trials Update Research Newsletter--August 2011 Issue
  
• Clinical Trials Update Research Newsletter--May 2011 Issue
  
• Clinical Trials Update Research Newsletter--February 2011 Issue
  

Patient Newsletter

• CareConnection-A special publication for patients by Cancer Care Centers of South Texas
  

  November 2011 issue

• CareConnection-A special publication for patient by Cancer Care Centers of South Texas
  

  September 2011 issue